Microbiota impact on the epigenetic regulation of colorectal cancer

Trends in Molecular Medicine

Volumn 19, Issue 12, 2013, Pages 714-725

  Yang, Tao ^a,b   Owen, Jennifer L ^a,b   Lightfoot, Yaíma L ^a,b   Kladde, Michael P ^a   Mohamadzadeh, Mansour ^a,b  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Colorectal cancer; Commensal bacteria; Epigenetic regulation; Inflammatory bowel disease; Microbiota

Indexed keywords

PROBIOTIC AGENT;

CANCER GENETICS; COLORECTAL CANCER; ENTERITIS; EPIGENETICS; GENE CONTROL; GENE PRODUCT; GENETIC ENGINEERING; HUMAN; IMMUNOREGULATION; INTESTINE FLORA; NONHUMAN; REVIEW;

COLORECTAL CANCER; COMMENSAL BACTERIA; EPIGENETIC REGULATION; INFLAMMATORY BOWEL DISEASE; MICROBIOTA;

ANIMALS; BACTERIA; COLORECTAL NEOPLASMS; EPIGENESIS, GENETIC; GASTROINTESTINAL TRACT; HUMANS; MICROBIOTA;

EID: 84888435366     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2013.08.005     Document Type: Review

References (114)

1. Ferlay J., et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 2010, 127:2893-2917.
2. Tjalsma H., et al. A bacterial driver-passenger model for colorectal cancer: beyond the usual suspects. Nat. Rev. Microbiol. 2012, 10:575-582.
3. Tudek B., Speina E. Oxidatively damaged DNA and its repair in colon carcinogenesis. Mutat. Res. 2012, 736:82-92.
4. Arends M.J. Pathways of colorectal carcinogenesis. Appl. Immunohistochem. Mol. Morphol. 2013, 21:97-102.
5. Fearon E.R. Molecular genetics of colorectal cancer. Annu. Rev. Pathol. 2011, 6:479-507.
6. Bierne H., Cossart P. When bacteria target the nucleus: the emerging family of nucleomodulins. Cell. Microbiol. 2012, 14:622-633.
7. Tosolini M., et al. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res. 2011, 71:1263-1271.
8. Couturier-Maillard A., et al. NOD2-mediated dysbiosis predisposes mice to transmissible colitis and colorectal cancer. J. Clin. Invest. 2013, 123:700-711.
9. Cario E. Microbiota and innate immunity in intestinal inflammation and neoplasia. Curr. Opin. Gastroenterol. 2013, 29:85-91.
10. Viladomiu M., et al. Nutritional protective mechanisms against gut inflammation. J. Nutr. Biochem. 2013, 24:929-939.
11. Ford A.C., et al. Ulcerative colitis. BMJ 2013, 346:f432.
12. Sansone P., Bromberg J. Environment, inflammation, and cancer. Curr. Opin. Genet. Dev. 2011, 21:80-85.
13. Jess T., et al. Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin. Gastroenterol. Hepatol. 2012, 10:639-645.
14. Okayasu I. Development of ulcerative colitis and its associated colorectal neoplasia as a model of the organ-specific chronic inflammation-carcinoma sequence. Pathol. Int. 2012, 62:368-380.
15. Mazeh H., et al. The diagnostic and prognostic role of microRNA in colorectal cancer - a comprehensive review. J. Cancer 2013, 4:281-295.
16. Vogelstein B., et al. Genetic alterations during colorectal-tumor development. N. Engl. J. Med. 1988, 319:525-532.
17. Al-Sohaily S., et al. Molecular pathways in colorectal cancer. J. Gastroenterol. Hepatol. 2012, 27:1423-1431.
18. Dongarra M.L., et al. Mucosal immunology and probiotics. Curr. Allergy Asthma Rep. 2013, 13:19-26.
19. Sekirov I., et al. Gut microbiota in health and disease. Physiol. Rev. 2010, 90:859-904.
20. Barengolts E. Vitamin D and prebiotics may benefit the intestinal microbacteria and improve glucose homeostasis in prediabetes and type 2 diabetes. Endocr. Pract. 2013, 19:497-510. 10.4158/EP12263.RA.
21. Winter S.E., et al. The dynamics of gut-associated microbial communities during inflammation. EMBO Rep. 2013, 14:319-327.
22. Darfeuille-Michaud A., et al. High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. Gastroenterology 2004, 127:412-421.
23. Rolhion N., et al. Abnormally expressed ER stress response chaperone Gp96 in CD favours adherent-invasive Escherichia coli invasion. Gut 2010, 59:1355-1362.
24. Ley R.E., et al. Obesity alters gut microbial ecology. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:11070-11075.
25. Arthur J.C., Jobin C. The struggle within: microbial influences on colorectal cancer. Inflamm. Bowel Dis. 2011, 17:396-409.
26. Kelly D., Mulder I.E. Microbiome and immunological interactions. Nutr. Rev. 2012, 70(Suppl. 1):S18-S30.
27. Dominguez-Bello M.G., et al. Development of the human gastrointestinal microbiota and insights from high-throughput sequencing. Gastroenterology 2011, 140:1713-1719.
28. Mulder I.E., et al. Restricting microbial exposure in early life negates the immune benefits associated with gut colonization in environments of high microbial diversity. PLoS ONE 2011, 6:e28279.
29. Nicholson J.K., et al. Host-gut microbiota metabolic interactions. Science 2012, 336:1262-1267.
30. Ivanov I.I., et al. Specific microbiota direct the differentiation of IL-17-producing T-helper cells in the mucosa of the small intestine. Cell Host Microbe 2008, 4:337-349.
31. + regulatory T cells in the lamina propria. Immunity 2011, 34:237-246.
32. Capelluto D.G. Tollip: a multitasking protein in innate immunity and protein trafficking. Microbes Infect. 2012, 14:140-147.
33. Min/+ mice. Oncogene 2013, 10.1038/onc.2012.581.
34. Fung K.Y., et al. A review of the potential mechanisms for the lowering of colorectal oncogenesis by butyrate. Br. J. Nutr. 2012, 108:820-831.
35. Leonel A.J., Alvarez-Leite J.I. Butyrate: implications for intestinal function. Curr. Opin. Clin. Nutr. Metab. Care 2012, 15:474-479.
36. Iwai K. Diverse ubiquitin signaling in NF-κB activation. Trends Cell Biol. 2012, 22:355-364.
37. Sakamoto K., et al. Constitutive NF-κB activation in colorectal carcinoma plays a key role in angiogenesis, promoting tumor growth. Clin. Cancer Res. 2009, 15:2248-2258.
38. Manichanh C., et al. The gut microbiota in IBD. Nat. Rev. Gastroenterol. Hepatol. 2012, 9:599-608.
39. Kipanyula M.J., et al. Signaling pathways bridging microbial-triggered inflammation and cancer. Cell. Signal. 2013, 25:403-416.
40. Sears C.L., Pardoll D.M. Perspective: alpha-bugs, their microbial partners, and the link to colon cancer. J. Infect. Dis. 2011, 203:306-311.
41. Azcarate-Peril M.A., et al. The intestinal microbiota, gastrointestinal environment and colorectal cancer: a putative role for probiotics in prevention of colorectal cancer?. Am. J. Physiol. Gastrointest. Liver Physiol. 2011, 301:G401-G424.
42. Yongvanit P., et al. Oxidative and nitrative DNA damage: key events in opisthorchiasis-induced carcinogenesis. Parasitol. Int. 2012, 61:130-135.
43. Mangerich A., et al. Infection-induced colitis in mice causes dynamic and tissue-specific changes in stress response and DNA damage leading to colon cancer. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:E1820-E1829.
44. Fox J.G., et al. Helicobacter hepaticus infection in mice: models for understanding lower bowel inflammation and cancer. Mucosal Immunol. 2011, 4:22-30.
45. Lao V.V., et al. Incorporation of 5-chlorocytosine into mammalian DNA results in heritable gene silencing and altered cytosine methylation patterns. Carcinogenesis 2009, 30:886-893.
46. Winter S.E., et al. Host-derived nitrate boosts growth of E. coli in the inflamed gut. Science 2013, 339:708-711.
47. Arthur J.C., et al. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science 2012, 338:120-123.
48. Wu S., et al. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat. Med. 2009, 15:1016-1022.
49. Schaible T.D., et al. Maternal methyl-donor supplementation induces prolonged murine offspring colitis susceptibility in association with mucosal epigenetic and microbiomic changes. Hum. Mol. Genet. 2011, 20:1687-1696.
50. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
51. Wu W.K., et al. Dysregulation and crosstalk of cellular signaling pathways in colon carcinogenesis. Crit. Rev. Oncol. Hematol. 2012, 86:251-277.
52. Christie M., et al. Different APC genotypes in proximal and distal sporadic colorectal cancers suggest distinct WNT/β-catenin signalling thresholds for tumourigenesis. Oncogene 2012, 10.1038/onc.2012.486.
53. Robanus-Maandag E.C., et al. A new conditional Apc-mutant mouse model for colorectal cancer. Carcinogenesis 2010, 31:946-952.
54. Khazaie K., et al. Abating colon cancer polyposis by Lactobacillus acidophilus deficient in lipoteichoic acid. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:10462-10467.
55. Shaked H., et al. Chronic epithelial NF-κB activation accelerates APC loss and intestinal tumor initiation through iNOS up-regulation. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:14007-14012.
56. Wei J., et al. p53 family: role of protein isoforms in human cancer. J. Nucleic Acids 2012, 2012:687359.
57. Markowitz S.D., Bertagnolli M.M. Molecular origins of cancer: molecular basis of colorectal cancer. N. Engl. J. Med. 2009, 361:2449-2460.
58. Bacolod M.D., Barany F. Gene dysregulations driven by somatic copy number aberrations - biological and clinical implications in colon tumors: a paper from the 2009 William Beaumont Hospital Symposium on Molecular Pathology. J. Mol. Diagn. 2010, 12:552-561.
59. Boland C.R., Goel A. Microsatellite instability in colorectal cancer. Gastroenterology 2010, 138:2073-2087.
60. Albuquerque C., et al. Colorectal cancers choosing sides. Biochim. Biophys. Acta 2011, 1816:219-231.
61. Feinberg A.P., Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 1983, 301:89-92.
62. Sharma S., et al. Epigenetics in cancer. Carcinogenesis 2010, 31:27-36.
63. Crea F., et al. Polycomb genes and cancer: time for clinical application?. Crit. Rev. Oncol. Hematol. 2012, 83:184-193.
64. Bronevetsky Y., Ansel K.M. Regulation of miRNA biogenesis and turnover in the immune system. Immunol. Rev. 2013, 253:304-316.
65. Iorio M.V., Croce C.M. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol. Med. 2012, 4:143-159.
66. Fabbri M. TLRs as miRNA receptors. Cancer Res. 2012, 72:6333-6337.
67. Kong Y.W., et al. microRNAs in cancer management. Lancet Oncol. 2012, 13:e249-e258.
68. Turchinovich A., et al. Characterization of extracellular circulating microRNA. Nucleic Acids Res. 2011, 39:7223-7233.
69. Wu C.W., et al. MicroRNA-18a attenuates DNA damage repair through suppressing the expression of ataxia telangiectasia mutated in colorectal cancer. PLoS ONE 2013, 8:e57036.
70. Stracker T.H., et al. The ATM signaling network in development and disease. Front. Genet. 2013, 4:37.
71. Sperka T., et al. DNA damage checkpoints in stem cells, ageing and cancer. Nat. Rev. Mol. Cell Biol. 2012, 13:579-590.
72. Migheli F., et al. Comparison study of MS-HRM and pyrosequencing techniques for quantification of APC and CDKN2A gene methylation. PLoS ONE 2013, 8:e52501.
73. Toyota M., et al. CpG island methylator phenotype in colorectal cancer. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:8681-8686.
74. Fan X.Y., et al. Association between RUNX3 promoter methylation and gastric cancer: a meta-analysis. BMC Gastroenterol. 2011, 11:92.
75. Nishio M., et al. RUNX3 promoter methylation in colorectal cancer: its relationship with microsatellite instability and its suitability as a novel serum tumor marker. Anticancer Res. 2010, 30:2673-2682.
76. Lee B.B., et al. Aberrant methylation of APC, MGMT, RASSF2A, and Wif-1 genes in plasma as a biomarker for early detection of colorectal cancer. Clin. Cancer Res. 2009, 15:6185-6191.
77. Mirchev M.B., et al. DNA methylation in patients with colorectal cancer - correlation with some clinical and morphological features and with local tumour invasion. Folia Med. (Plovdiv) 2010, 52:22-30.
78. Drini M., et al. Investigating the potential role of genetic and epigenetic variation of DNA methyltransferase genes in hyperplastic polyposis syndrome. PLoS ONE 2011, 6:e16831.
79. Curtin N.J. DNA repair dysregulation from cancer driver to therapeutic target. Nat. Rev. Cancer 2012, 12:801-817.
80. Ito Y. RUNX genes in development and cancer: regulation of viral gene expression and the discovery of RUNX family genes. Adv. Cancer Res. 2008, 99:33-76.
81. Ito K., et al. RUNX3 attenuates β-catenin/T cell factors in intestinal tumorigenesis. Cancer Cell 2008, 14:226-237.
82. Chuang L.S., Ito Y. RUNX3 is multifunctional in carcinogenesis of multiple solid tumors. Oncogene 2010, 29:2605-2615.
83. Ku J.L., et al. Promoter hypermethylation downregulates RUNX3 gene expression in colorectal cancer cell lines. Oncogene 2004, 23:6736-6742.
84. Kim J.H., et al. Subsets of microsatellite-unstable colorectal cancers exhibit discordance between the CpG island methylator phenotype and MLH1 methylation status. Mod. Pathol. 2013, 26:1013-1022.
85. Schwitalla S., et al. Intestinal tumorigenesis initiated by dedifferentiation and acquisition of stem-cell-like properties. Cell 2013, 152:25-38.
86. Feinberg A.P., et al. The epigenetic progenitor origin of human cancer. Nat. Rev. Genet. 2006, 7:21-33.
87. Baker S.J., et al. p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res. 1990, 50:7717-7722.
88. Tulchin N., et al. c-myc protein distribution. Neoplastic tissues of the human colon. Am. J. Pathol. 1992, 140:719-729.
89. Tulchin N., et al. C-myc protein distribution - mammary adenocarcinomas of mtv/myc transgenic mice. Int. J. Oncol. 1995, 7:5-9.
90. Struhl K., Segal E. Determinants of nucleosome positioning. Nat. Struct. Mol. Biol. 2013, 20:267-273.
91. Fraga M.F., et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat. Genet. 2005, 37:391-400.
92. Barski A., et al. High-resolution profiling of histone methylations in the human genome. Cell 2007, 129:823-837.
93. Chase A., Cross N.C. Aberrations of EZH2 in cancer. Clin. Cancer Res. 2011, 17:2613-2618.
94. Grimm C., et al. DNA-methylome analysis of mouse intestinal adenoma identifies a tumour-specific signature that is partly conserved in human colon cancer. PLoS Genet. 2013, 9:e1003250.
95. Kan P.Y., et al. The H4 tail domain participates in intra- and internucleosome interactions with protein and DNA during folding and oligomerization of nucleosome arrays. Mol. Cell. Biol. 2009, 29:538-546.
96. Shogren-Knaak M., et al. Histone H4-K16 acetylation controls chromatin structure and protein interactions. Science 2006, 311:844-847.
97. Hassan A.H., et al. Histone acetyltransferase complexes stabilize SWI/SNF binding to promoter nucleosomes. Cell 2001, 104:817-827.
98. Akhavan-Niaki H., Samadani A.A. DNA methylation and cancer development: molecular mechanism. Cell Biochem. Biophys. 2013, (in press).
99. Wilson A.J., et al. Apoptotic sensitivity of colon cancer cells to histone deacetylase inhibitors is mediated by an Sp1/Sp3-activated transcriptional program involving immediate-early gene induction. Cancer Res. 2010, 70:609-620.
100. Lee Y.M. Control of RUNX3 by histone methyltransferases. J. Cell. Biochem. 2011, 112:394-400.
101. Icardi L., et al. The HAT/HDAC interplay: multilevel control of STAT signaling. Cytokine Growth Factor Rev. 2012, 23:283-291.
102. Fahrner J.A., et al. Dependence of histone modifications and gene expression on DNA hypermethylation in cancer. Cancer Res. 2002, 62:7213-7218.
103. Park S.Y., et al. Comparison of CpG island hypermethylation and repetitive DNA hypomethylation in premalignant stages of gastric cancer, stratified for Helicobacter pylori infection. J. Pathol. 2009, 219:410-416.
104. Ding S.Z., et al. Helicobacter pylori-induced histone modification, associated gene expression in gastric epithelial cells, and its implication in pathogenesis. PLoS ONE 2010, 5:e9875.
105. Kellermayer R., et al. Colonic mucosal DNA methylation, immune response, and microbiome patterns in Toll-like receptor 2-knockout mice. FASEB J. 2011, 25:1449-1460.
106. Rius M., Lyko F. Epigenetic cancer therapy: rationales, targets and drugs. Oncogene 2012, 31:4257-4265.
107. Licciardi P.V., et al. Epigenome targeting by probiotic metabolites. Gut Pathog. 2010, 2:24.
108. Ritchie M.L., Romanuk T.N. A meta-analysis of probiotic efficacy for gastrointestinal diseases. PLoS ONE 2012, 7:e34938.
109. Mohamadzadeh M., et al. Regulation of induced colonic inflammation by Lactobacillus acidophilus deficient in lipoteichoic acid. Proc. Natl. Acad. Sci. U.S.A. 2011, 108(Suppl. 1):4623-4630.
110. Saber R., et al. Lipoteichoic acid-deficient Lactobacillus acidophilus regulates downstream signals. Immunotherapy 2011, 3:337-347.
111. Lightfoot Y.L., et al. Targeting aberrant colon cancer-specific DNA methylation with lipoteichoic acid-deficient Lactobacillus acidophilus. Gut Microbes 2013, 4:84-88.
112. Hedin C., et al. Evidence for the use of probiotics and prebiotics in inflammatory bowel disease: a review of clinical trials. Proc. Nutr. Soc. 2007, 66:307-315.
113. Marteau P.R., et al. Protection from gastrointestinal diseases with the use of probiotics. Am. J. Clin. Nutr. 2001, 73:430S-436S.
114. Ghadimi D., et al. Epigenetic imprinting by commensal probiotics inhibits the IL-23/IL-17 axis in an in vitro model of the intestinal mucosal immune system. J. Leukoc. Biol. 2012, 92:895-911.